Wealth Effects LLC Avadel Pharmaceuticals PLC Transaction History

Wealth Effects LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 22, 2024	SELL	$12.55 - $17.22 $1.91 Million - $2.62 Million	-152,100 Reduced 6.29%	2,264,226 $38.2 Million
Q4 2023 Jan 29, 2024	BUY	$9.64 - $14.59 $67,836 - $102,669	7,037 Added 0.29%	2,416,326 $34.1 Million
Q3 2023 Oct 16, 2023	BUY	$10.3 - $15.99 $414,060 - $642,798	40,200 Added 1.7%	2,409,289 $24.8 Million
Q2 2023 Jul 18, 2023	SELL	$8.48 - $16.48 $1.1 Million - $2.14 Million	-129,749 Reduced 5.19%	2,369,089 $39 Million
Q1 2023 May 04, 2023	SELL	$6.41 - $9.95 $102,989 - $159,866	-16,067 Reduced 0.64%	2,498,838 $22.9 Million
Q4 2022 Feb 02, 2023	SELL	$5.02 - $10.0 $400,872 - $798,550	-79,855 Reduced 3.08%	2,514,905 $18 Million
Q3 2022 Nov 14, 2022	BUY	$2.57 - $7.31 $27,421 - $77,997	10,670 Added 0.41%	2,594,760 $13 Million
Q2 2022 Aug 03, 2022	BUY	$1.07 - $6.95 $221,276 - $1.44 Million	206,800 Added 8.7%	2,584,090 $6.31 Million
Q1 2022 May 16, 2022	BUY	$5.46 - $8.29 $394,610 - $599,143	72,273 Added 3.14%	2,377,290 $16.2 Million
Q4 2021 Feb 09, 2022	BUY	$7.34 - $11.18 $16.9 Million - $25.8 Million	2,305,017 New	2,305,017 $18.6 Million

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $650M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Wealth Effects LLC, based on Form 13F filings with the SEC.

Stay updated on Wealth Effects LLC with notifications on news.